Pomerantz LLP is investigating Lenz Therapeutics for possible securities fraud following the company's Q2 2026 report showing flat sales for its main eye drop product, VIZZ, and reliance on one-time licensing revenue. Bank of America downgraded Lenz's stock and cut its price target drastically, leading to a sharp stock price drop that hurt investors. The investigation will determine if Lenz's officers engaged in unlawful practices. Investors impacted by the decline are encouraged to contact Pomerantz LLP for potential class action participation.
THC-infused beverages in the US saw a 135% sales increase to $239 million over the past year, becoming a popular alcohol alternative. However, a potential federal ban on hemp-derived THC products is causing distributors to hesitate on restocking, imp...
Sigma Lithium has been approved for listing on the Australian Securities Exchange (ASX) as a Foreign Exempt Issuer, starting official trading on September 3, 2026, under the ticker SAU. This listing broadens the company's access to a sophisticated in...
Sharon AI has entered a five-year strategic agreement with Rafay Systems to use Rafay's platform as a centralized orchestration and operations layer across its AI Factory environments. This platform will standardize how Sharon AI manages its AI infra...
VersaBank, a digital business-to-business bank and cybersecurity technology provider, announced its management will participate in the Raymond James US Bank and Banking on Tech Conference in Chicago from September 8-10, 2026. The bank operates with a...
KeyCorp announced that its Chief Financial Officer, Clark Khayat, will present at the Barclays Global Financial Services Conference on September 14, 2026. During the presentation, KeyCorp will review its recent performance, strategic plans, and futur...
